<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808949</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-029/IPM 039</org_study_id>
    <nct_id>NCT02808949</nct_id>
    <nct_alias>NCT02658227</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women</brief_title>
  <official_title>Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 PK Study of the Dapivirine Vaginal Ring in Lactating Women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PK Study of the Dapivirine Vaginal Ring in Lactating Women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 3, 2018</completion_date>
  <primary_completion_date type="Actual">March 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>14 Days</time_frame>
    <description>To assess the pharmacokinetics of dapivirine vaginal ring used for 14 consecutive days in lactating women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dapivirine ring in lactating women</measure>
    <time_frame>14 days</time_frame>
    <description>To assess safety and tolerability of dapivirine vaginal ring used for 14 consecutive days in lactating women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to dapivirine vaginal ring use in lactating women</measure>
    <time_frame>14 days</time_frame>
    <description>To assess adherence to dapivirine vaginal ring use in lactating women</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Age Groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine</intervention_name>
    <description>Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.</description>
    <arm_group_label>Age Groups</arm_group_label>
    <other_name>Dapivirine vaginal ring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women must meet all of the following criteria (by self-report, unless otherwise indicated)
        to be eligible for inclusion in the study:

          1. Age 18 or older at screening as verified per site SOP

          2. Per participant report, at least 6 weeks postpartum at Enrollment

          3. Willing and able to provide written informed consent to be screened for and take part
             in the study

          4. Willing and able to provide adequate locator information, as defined in site SOP

          5. Willing and able to communicate in spoken and written English

          6. HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix
             II and willing to receive HIV test results Note: HIV-1/2 screening may be omitted at
             Enrollment if the time between Screening and Enrollment is &lt; 30 days

          7. Prior to Enrollment, breastfeeding of child has stopped

          8. Participant has no intention of providing expressed breast milk to her child(ren) or
             to others for consumption after initiation of study product Note: Providing stored
             breast milk to child(ren) that has been expressed prior to study product exposure is
             not exclusionary

          9. Willing and able to express breast milk at least twice daily for the duration of study
             drug exposure

         10. Per participant report, using an effective method of contraception at Enrollment, and
             intending to continue the use of an effective method for the duration of study
             participation. Effective methods for MTN-029/IPM 039 include: hormonal methods (except
             contraceptive VRs), intrauterine device (IUD) inserted at least 28 days prior to
             enrollment, engages in sex exclusively with women, sterilized (self or partner), or
             sexually abstinent for the past 90 days

         11. Women over the age of 21 (inclusive) must have documentation of a satisfactory Pap
             within the past 3 years prior to Enrollment consistent with Grade 0 according to the
             Female Genital Grading Table for Use in Microbicide Studies (Addendum 1 to the DAIDS
             Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0,
             November 2007), or satisfactory evaluation with no treatment required of Grade 1 or
             higher Pap result

         12. At Screening, participant states a willingness to refrain from receptive sexual
             activity (including penile-vaginal intercourse, anal intercourse, receptive oral
             intercourse, finger stimulation) and from inserting any non-study objects into the
             vagina (including tampons, sex toys, female condoms, diaphragms, menstrual cups,
             cervical caps or any other vaginal barrier method, etc.), for 24 hours prior to each
             clinic visit.

         13. At Screening, participant states a willingness to refrain from the use of vaginal
             products, including, spermicides, lubricants, contraceptive VRs, douches, vaginal
             medications, etc., for the duration of study participation

         14. Per participant report at Screening and Enrollment, agrees not to participate in other
             research studies involving drugs, medical devices, vaginal products, vaccines or
             breast milk sampling for the duration of study participation Note: Participation in
             observational studies is not exclusionary

        Exclusion Criteria:

        Women who meet any of the following criteria (by self-report, unless otherwise indicated)
        will be excluded from the study:

          1. Participant report of any of the following:

               -  History of adverse reaction to any component of dapivirine VR

               -  Participation in investigational drug or device trial within 30 days prior to the
                  Enrollment Visit (Day 0)

               -  Use of vaginal medication(s) 5 days prior to Enrollment (Day 0)

               -  Complication of lactation requiring treatment, e.g., mastitis

          2. At the time of Screening and Enrollment, clinical evidence of milk supply less than 1
             ounce per expression

          3. As determined by the IoR/designee, any significant uncontrolled active or chronic
             cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,
             endocrine, respiratory, immunologic disorder or infectious disease

          4. Grade 2 or higher AST/ALT at Screening Visit:

             Note: Otherwise eligible participants with an exclusionary AST/ALT may be retested
             during the screening process.

          5. Positive urine pregnancy test at screening or enrollment

          6. Diagnosed with urinary tract infection (UTI) at Screening or Enrollment Note:
             Otherwise eligible participants diagnosed with UTI during screening are offered
             treatment and may be enrolled after completing treatment and all symptoms have
             resolved.

          7. Diagnosed with an STI or a reproductive tract infection (RTI) requiring treatment per
             current Centers for Disease Control and Prevention (CDC) guidelines at Screening or
             Enrollment

          8. On pelvic exam, any of the following findings:

               -  Incomplete postpartum involution of the uterus

               -  Clinically apparent Grade 2 or higher pelvic exam finding (observed by study
                  staff)

          9. Use of oral and/or vaginal preparations of antibiotic or antifungal medications within
             5 days of Enrollment

         10. At Screening or Enrollment, any social or medical condition that, in the
             investigator's opinion, would preclude informed consent, make study participation
             unsafe, complicate interpretation of study outcome data, or otherwise interfere with
             achieving the study objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Hoesley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magee-Womens Hospital of UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Lactating Women</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

